SCHEMBL599087

SCHEMBL599087

CCCC(C)C(C)(C)CC

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.33
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27767319 0.86
SCHEMBL7756753 0.83 DNM1 (0.36) TSHRTDP1
SCHEMBL20609980 0.81 OPRM1 (0.44) TSHR
SCHEMBL21925384 0.80 TSHR (0.32) TSHR
SCHEMBL21925370 0.80 TSHR (0.30) TSHRTDP1
SCHEMBL29209888 0.79 OPRM1 (0.42) TSHR
SCHEMBL2761465 0.79 OPRM1 (0.42) TSHR
SCHEMBL21157519 0.78 GABRR1 (0.32)
SCHEMBL4947662 0.78 DPP4 (0.31) TSHR
SCHEMBL12986529 0.78 TSHR (0.31) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062631-A1 CYCLOOCTANE CONTAINING FUEL COMPOSITIONS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2026-03-05 US claimed
US-20240140888-A1 COMPOSITION COMPRISING AN ALKANE AND AN OXOESTER BIOSYNTHIS (FR) 2024-05-02 US claimed
EP-4321651-A1 COMPOSITION COMPRISING AN ALKANE AND AN OXO ESTER Biosynthis (FR) 2024-02-14 EP claimed
EP-2829555-B1 METHOD FOR PRODUCING OLEFIN POLYMER MITSUI CHEMICALS INC (JP) 2018-05-16 EP claimed
CN-104203993-B Process for producing olefin polymer 三井化学株式会社 2016-06-15 CN claimed
US-9315602-B2 Method for producing olefin polymer MITSUI CHEMICALS, INC. (JP) 2016-04-19 US claimed
US-12616728-B2 Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same SUPER CRITICAL IP, LLC (US) 2026-05-05 US disclosed
US-20260062631-A1 CYCLOOCTANE CONTAINING FUEL COMPOSITIONS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2026-03-05 US disclosed
US-20260041617-A1 COSMETIC COMPOSITION APPLICABLE TO THE SKIN AND BASED ON A VOLATILE MIXTURE OF ALKANES BIOSYNTHIS (FR) 2026-02-12 US disclosed
US-12503662-B1 Cyclooctane containing seal swelling compositions and methods for use of same CleanJoule, Inc. (US) 2025-12-23 US disclosed
US-20250197341-A1 METHOD FOR INHIBITING CRYSTALLISATION BIOSYNTHIS (FR) 2025-06-19 US disclosed
US-20250177263-A1 LIPSTICK COMPOSITION BASED ON A VOLATILE MIXTURE OF ALKANES BIOSYNTHIS (FR) 2025-06-05 US disclosed
US-20250170037-A1 EYE MAKEUP COMPOSITION BASED ON A VOLATILE MIXTURE OF ALKANES BIOSYNTHIS (FR) 2025-05-29 US disclosed
EP-1461041-A2 PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES Pharmasset Ltd. (BB) 2004-09-29 EP disclosed
US-20030176319-A1 For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts GILEAD PHARMASSET LLC 2003-09-18 US disclosed
US-20030162992-A1 Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde PHARMASSET, INC. 2003-08-28 US disclosed
WO-2003063771-A2 N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS PHARMASSET LTD. (BB) 2003-08-07 WO disclosed
WO-2003051298-A2 PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES PHARMASSET LTD. (BB) 2003-06-26 WO disclosed
WO-2003051306-A2 N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS PHARMASSET LTD. (BB) 2003-06-26 WO disclosed
US-4214116-A Hydrocarbon isomerization utilizing a hydrocarbon promoter with tantalum pentafluoride and hydrogen halide catalyst STANDARD OIL CO. (INDIANA) (US) 1980-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616728-B2 Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same CNR2, CNR1, SCD TSHR 2794/4885TDP1 4427/4885
US-20240140888-A1 COMPOSITION COMPRISING AN ALKANE AND AN OXOESTER ALKBH2, ABHD12, FAAH2 TSHR 3034/4885TDP1 2123/4885
US-20260041617-A1 COSMETIC COMPOSITION APPLICABLE TO THE SKIN AND BASED ON A VOLATILE MIXTURE OF ALKANES CUTA, AP2M1, LBR TSHR 612/4885TDP1 1620/4885
US-12503662-B1 Cyclooctane containing seal swelling compositions and methods for use of same AQP1, GJA1, DSC1 TSHR 4878/4885TDP1 1783/4885
US-20260062631-A1 CYCLOOCTANE CONTAINING FUEL COMPOSITIONS CPT1A, CPT2, CNR2 TSHR 3620/4885TDP1 1781/4885
US-20030176319-A1 For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts ENTPD5, CDA, ADA TSHR 4374/4885TDP1 1215/4885
US-20250197341-A1 METHOD FOR INHIBITING CRYSTALLISATION FASN, SCD5, NFKB2 TSHR 3901/4885TDP1 3078/4885
US-20030162992-A1 Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde DERA, DPYD, DHPS TSHR 3766/4885TDP1 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.